Holger Reithinger, PhD
Holger joined Forbion in 2010, heading the Munich office.
Holger is General Partner and heads the Munich Office of Forbion has a key role in the investment team, with investment experience both in biopharma as medical devices. Holger currently holds board seats at Curetis (IPO 2015), Cellnovo (IPO 2015), Allecra and catalYm. He is also member of the investment committee of the Hightech-Gründer Fonds, Germany’s biggest early-stage and seed investor.
Holger has served on the Boards of numerous life sciences companies including Epigenomics* (IPO 2004), MBT* (assets sold to Medigene), 4SC* (IPO 2005), NeurogesX* (IPO 2007), Fibrex Medical* (assets licensed to Ikaria), Agendia*, Santaris* (sold to Roche) and Rigontec (sold to MSD).
Holger joined Forbion in 2010, setting up its Munich office. Prior to joining Forbion, Holger was Partner at Global Life Science Ventures (a life sciences-focused partnership with offices in Switzerland and Germany) and Director at Germany's healthcare practice of 3i and Investment Manager at Technologieholding VC, at the time one of the leading German Venture Capital firms, respectively. Prior to his VC activities, Holger gained operational experience as a product development manager at Biometra/Whatman Plc, now part of GE Healthcare.
Holger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. He holds a PhD in Biochemistry from the Max-Planck-Institute of Biophysics, which he obtained under the supervision of Prof. Dr. Arne Skerra in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988)
*) prior to joining Forbion